GMP IPO Watch
Motilal Oswal Nifty MidSmall Healthcare Index Fund
Direct Plan · Growth · Motilal Oswal Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | -2.56% | -0.80% | 277 of 293 |
| 1M | -3.02% | -3.85% | 93 of 293 |
| 3M | -1.03% | -3.10% | 101 of 292 |
| 6M | +20.51% | +5.77% | 10 of 281 |
| YTD | +14.64% | -3.05% | 6 of 293 |
| 1Y | +14.93% | -0.26% | 8 of 265 |
| INCEPTION | +10.11% | — | — |
Ranked among: Other Scheme - Index Funds.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +3.91% | +21.76% | -14.53% | 64% | 26% |
| 6M | +7.51% | +29.70% | -10.25% | 70% | 29% |
| 1Y | +10.54% | +20.88% | -2.12% | 91% | 39% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Aug 2026
Asset Allocation
- Equity100.31%
- Debt0.00%
- Cash-0.31%
- Other0.00%
Market Cap Split
- Large Cap0.00%
- Mid Cap67.57%
- Small Cap32.43%
- Others0.00%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 39.29 | 24.36 |
| P/B | 5.52 | 4.03 |
| Price / Sales | 5.71 | 3.39 |
| Price / Cash Flow | 27.65 | 17.92 |
| Dividend Yield (%) | 0.41 | 1.51 |
Holdings · Aug 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Laurus Labs | Pharmaceuticals & Biotechnology | 11.23% | +0.46% |
| Lupin | Pharmaceuticals & Biotechnology | 8.01% | -0.93% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 7.16% | +0.50% |
| Fortis Healthcare | Equity | 7.12% | -0.38% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 5.63% | +0.50% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 4.70% | -0.43% |
| Biocon | Pharmaceuticals & Biotechnology | 4.43% | -0.20% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 4.13% | +0.43% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 4.11% | -0.15% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 3.46% | +0.42% |
| Aster DM Quality Care | Equity | 3.05% | -0.12% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 3.03% | +0.27% |
| Neuland Laboratories | Pharmaceuticals & Biotechnology | 2.99% | +0.49% |
| Krishna Institute of Medical Sciences | Equity | 2.95% | -0.23% |
| Acutaas Chemicals | Pharmaceuticals & Biotechnology | 2.47% | +0.02% |
View all 31 holdings
| Wockhardt | Pharmaceuticals & Biotechnology | 2.34% | -0.13% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 2.29% | +0.07% |
| Dr. Lal Path Labs | Equity | 2.27% | +0.01% |
| Abbott | Pharmaceuticals & Biotechnology | 2.03% | -0.18% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 2.01% | +0.16% |
| Narayana Hrudayalaya | Equity | 1.99% | -0.15% |
| Global Health | Equity | 1.91% | +0.08% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 1.90% | +0.23% |
| Granules | Pharmaceuticals & Biotechnology | 1.81% | -0.01% |
| Onesource Specialty Pharma | Pharmaceuticals & Biotechnology | 1.80% | -0.14% |
| Syngene International | Equity | 1.15% | +0.03% |
| Natco Pharma | Pharmaceuticals & Biotechnology | 1.14% | -0.12% |
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 1.12% | +0.07% |
| Pfizer | Pharmaceuticals & Biotechnology | 1.07% | -0.04% |
| Poly Medicure | Equity | 1.01% | +0.02% |
| Net Receivables / (Payables) | Net Current Assets | -0.31% | — |
Sector Allocation · Aug 2026
Risk Metrics
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.80 | — | Good Risk Adjusted Returns |
What is this?
Higher the value means that fund has been able to give better returns for the amount of risk taken. It helps investors understand the return of an investment compared to its risk, showing whether the returns are due to intelligent investing or simply taking on excess risk. It is calculated by subtracting the risk-free return, defined as an Indian Government Bond, from the fund's returns, and then dividing by the standard deviation of returns.
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.39 | — | Good Risk Adjusted Returns |
What is this?
The Sortino Ratio is a financial metric used to measure the risk-adjusted return of an investment. It's a modification of the Sharpe Ratio but with a key difference; it only considers downside risk (the risk of negative returns), rather than total volatility. This means it focuses on how well an investment performs relative to the volatility that leads to losses, ignoring the volatility that results in gains. The idea is that investors are primarily concerned with minimizing losses, and positive volatility is generally seen as a good thing.
Tracking Difference
Versus Nifty MidSmall Healthcare - TRI, as of Aug 2026.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
ICICI Prudential NASDAQ 100 Index Fund
Regular Plan · Growth
|
+32.32% | +33.12% | — | +20.04% |
|
Motilal Oswal S&P 500 Index Fund
Direct Plan · GROWTH
|
+24.35% | +27.72% | +18.70% | +21.32% |
|
Tata Nifty Capital Markets Index Fund
Direct Plan · Growth Option
|
+20.98% | — | — | +19.34% |
|
Motilal Oswal Nifty Capital Market Index Fund
Regular Plan · Growth
|
+20.37% | — | — | +13.42% |
|
ICICI Prudential Nifty Pharma Index Fund
Direct Plan · IDCW
|
+20.08% | +20.30% | — | +20.51% |
|
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund
Direct Plan · Growth
|
+17.81% | +18.52% | +13.57% | +16.10% |
|
Tata Nifty MidSmall Healthcare Index Fund
Regular Plan · IDCW Payout Option
|
+14.44% | — | — | +16.34% |
|
Motilal Oswal Nifty MidSmall Financial Services Index Fund
Regular Plan · Growth
|
+13.42% | — | — | +16.65% |
|
Bandhan BSE Healthcare Index Fund
Regular Plan · Growth
|
+12.53% | — | — | +5.80% |
|
Motilal Oswal Nifty India Defence Index Fund
Regular Plan · Growth
|
+12.03% | — | — | +4.45% |
More From Motilal Oswal Asset Management Company Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| Motilal Oswal Silver ETF | +51.57% | — | — | +76.32% |
|
Motilal Oswal Nasdaq 100 Fund of Fund
Direct plan · Growth
|
+41.16% | +38.90% | +24.55% | +27.08% |
| Motilal Oswal Nasdaq Q50 ETF | +40.73% | +32.02% | — | +13.87% |
| Motilal Oswal Nasdaq 100 ETF | +33.73% | +33.90% | +21.91% | +23.84% |
|
Motilal Oswal Gold and Silver Passive Fund of Funds
Direct Plan · Growth
|
+31.75% | +38.49% | — | +32.35% |
|
Motilal Oswal Active Momentum Fund
Direct Plan · Reinvestment/Payout
|
+26.04% | — | — | +27.23% |
| Motilal Oswal Gold ETF | +24.99% | — | — | +39.39% |
|
Motilal Oswal Focused Fund
Direct Plan · Growth
|
+24.86% | +14.61% | +10.34% | +14.65% |
|
Motilal Oswal S&P 500 Index Fund
Direct Plan · GROWTH
|
+24.35% | +27.72% | +18.70% | +21.32% |
|
Motilal Oswal Developed Market Ex US ETFs Overseas Equity Passive FOF
Direct Plan · Growth
|
+23.27% | +23.10% | — | +23.05% |
About This Scheme
Investment Objective
The investment objective of the scheme is to provide returns that, before expenses, correspond to the total returns of the securities as represented by Nifty MidSmall Healthcare Total Return Index, subject to tracking error. However, there can be no assurance or guarantee that the investment objectives of the scheme will be achieved.
Exit Load
1% if redeemed on or before 15 days of allotment. Nil- If redeemed after 15 days from the date of allotment.
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.